Intersect ENT today announced that it has commercially launched its VenSure balloon sinus dilation system and Cube 4D navigation system in the U.S.
Menlo Park, Calif.-based Intersect ENT designed the VenSure balloon and Cube 4D navigation system to be used in procedures that improve debilitating chronic rhinosinusitis (CRS) symptoms. Cube 4D has VirtuEye photo registration that allows for easy 3D facial registration, pinpoint accuracy and improved workflow efficiency for balloon sinus dilation (BSD) procedures and other ENT-related skull-based surgeries, according to the company.
“Chronic rhinosinusitis is an underserved and serious condition that can reduce patients’ quality of life, their ability to work and to get restful sleep. There is a clear need for innovative tools and a broadened armamentarium that can help physicians treat patients suffering from CRS,” Rajiv Pandit, an otolaryngologist at Dallas ENT Head & Neck Surgery, said in a news release. “Balloon sinus dilation offers CRS patients a convenient, less-invasive, lower-cost solution by providing rapid resolution of symptoms with minimal risk of complications. The VenSure balloon allows the technique to be tailored and adapted to each patient’s unique anatomy and the use of the Cube Navigation System with VirtuEye ensures a simple yet highly precise location of the balloon for optimized placement within the sinus.”
In BSD procedures, the balloon is inserted to open the blocked sinuses with precision. It preserves the integrity of the sinus tissues and allows for quick recovery times. The procedure is also performed in the physician’s office.
The VenSure balloon has a slim ergonomic design to tailor to the physician’s hand for efficient maneuverability. Its responsive feel is driven by its malleability and components to optimize visibility and feel, according to the company.
Intersect ENT’s Cube 4D navigation system is an electromagnetic navigation system that integrates into any cart or tower shelf. It has on-screen instructions and audible confirmation tones to track preferred instrumentation. With VirtuEye, the system collects over 50,000 patient registration points in one camera shot to mitigate tactile tracing errors.
“Intersect ENT is transforming to become a more diversified, integrated and evidence-based growth company participating across the continuum of care in CRS,” president and CEO Thomas West said. “Our portfolio of related but distinct technologies inclusive of our localized drug delivery platforms, Propel and Sinuva, along with VenSure and Cube, now provide surgeon’s an integrated toolbox of solutions to treat patients suffering from CRS regardless of site of care. We are proud of our continued leadership in bringing to market innovative novel ENT technologies that address patient and physician need while providing significant growth to our company.”